A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies

This early-phase trial is testing a new drug called TQB3455 tablets in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) — serious blood cancers where the bone marrow produces abnormal blood cells. The study is evaluating both TQB3455 alone and in combination with other drugs to determine safety, dosing, and early signs of effectiveness. **You may be eligible if...** - You are 18 years of age or older - You have been diagnosed with AML that has relapsed (come back) or is refractory (not responding), OR - You are newly diagnosed with AML but are not considered a candidate for standard intensive chemotherapy due to age, physical condition, or risk factors, OR - You have high-risk or very high-risk MDS based on standard scoring - Your organ function meets the required levels **You may NOT be eligible if...** - You have active serious infections - You have had a recent organ or stem cell transplant - You are pregnant or breastfeeding - Your organ function is too impaired to tolerate the treatment Talk to your doctor to see if this trial is right for you.